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FDG-PET is a predictor of the metabolic response to chemotherapy in metastastic colorectal cancer 
patients (mCRC).  
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Abstract: 
 
Background: Limited information is available on the role of FDG-PET in the management of 
patients with mCRC. Bevacizumab prolongs overall survival and progression-free survival 
(PFS) when added to standard chemotherapy in mCRC patients. The purpose of the study was 
to explore the possible role of FDG-PET as response predictor for bevacizumab treatment in 
liver mCRC patients. Methods: Eighteen mCRC patients (7 women and 11 men), were treated 
with FOLFOX (n=12) or FOLFIRI (n=6) and bevacizumab (5 mg/kg). FDG-PET scans were 
performed before treatment (baseline) and median 15 days after cycle 5 (follow-up). PET 
scans were read by a nuclear medicine physician, blinded to the results of clinical parameters. 
The most representative liver lesion was used as target lesion. PET results were quantified by 
calculating the maximum standard uptake value (SUVmax) at baseline and follow-up. PFS 
was defined as the time from start of treatment to the date of first documented disease 
progression. Results: Median PFS was 10 months (95% CI: 8.51-11.49). The median baseline 
SUVmax was 5.18 (IQR: 3.61-8.42) and the median follow-up SUVmax was 2.93 (IQR: 2.15-
5.94; p=0.025). Following the EORTC criteria, FDG-PET revealed a complete metabolic 
response in 8 patients (44%), partial metabolic response in 3 patients (17%), stable metabolic 
disease in 3 patients (17%) and progressive metabolical disease in 4 patients (22%). 
Correlation between metabolic response and radiological response according to RECIST was 
as follows: 6 of the 8 patients with radiological response had metabolic response (sensitivity 
75%) and 5 out of 10 patients with radiological stable or progressive disease were metabolic 
non-responders (specificity 50%). Using the Cox proportional hazards model, the follow-up 
SUVmax (HR 1.33, 95% CI 1.000-1.776, p=0.05) showed a trend towards significant 
prediction of PFS. The Kaplan-Meier log rank test showed a PFS benefit for patients with 
>30% reduction in their SUVmax (p=0.02). Conclusions: The use of FDG-PET for therapy 
monitoring is clinically feasible and the follow-up SUVmax seems to be a promising predictor 
of PFS. 
